---
title: "AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: LunAIRo"
description: "Formulary evidence on AD109 (aroxybutynin-atomoxetine, Oxnimbi) in Obstructive sleep apnea: LunAIRo. Covers Objective, Location and study date, Study design, Eligibility criteria, Treatment, Study outcomes, and 3 further headings. 98 evidence topics quoted from 19 sources."
canonical: "https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/clinical-evidence/lunairo"
published: "2026-11-18T10:43:47-05:00"
modified: "2026-11-18T10:43:47-05:00"
---

# AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: LunAIRo

<a id="heading-3.1.2"></a>

## 3.1.2 LunAIRo

<a id="heading-3.1.2.1"></a>

### 3.1.2.1 Objective

<a id="topic-3.1.2.1-1"></a>

#### Primary and secondary objectives in the design paper

> “The primary objective of the LunAIRo and SynAIRgy trials is to demonstrate the efficacy of AD109 versus placebo for upper airway obstruction, as measured by the AHI4, among individuals across the full range of OSA severity, from mild to very severe, over a 26-week treatment period.”
> “Additional objectives for the LunAIRo trial include exploring both long-term efficacy and safety endpoints over a 51-week placebo-controlled period, and exploring time points as early as 4 weeks to evaluate rapid onset of efficacy of AD109.”

Source: [Taranto-Montemurro et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12490522/)

<a id="topic-3.1.2.1-2"></a>

#### Study rationale and purpose in the protocol

> “The present study, LunAIRo (APC-APN-304), is a Phase 3 study designed to examine the efficacy and safety of AD109 compared to placebo at 6-months and 1 year.”
> “The primary purpose of conducting this study is to show that AD109 is safe and superior to placebo for airway obstruction (AHI4).”

Source: [Apnimed LunAIRo protocol (2025)](https://cdn.clinicaltrials.gov/large-docs/47/NCT05811247/Prot_000.pdf)

<a id="topic-3.1.2.1-3"></a>

#### Brief summary in the ClinicalTrials.gov record

> “This is a Phase 3 Randomized Double-Blind Placebo-Controlled 1-year Parallel-Arm Study to Compare a Fixed Dose Combination of AD109 to Placebo in Obstructive Sleep Apnea.”

Source: [ClinicalTrials.gov NCT05811247](https://clinicaltrials.gov/study/NCT05811247)

<a id="heading-3.1.2.2"></a>

### 3.1.2.2 Location and Study Date

<a id="topic-3.1.2.2-1"></a>

#### Study dates in the ClinicalTrials.gov record

> “Study Start (Actual) 2023-08-28”
> “Primary Completion (Actual) 2025-05-07”
> “Study Completion (Actual) 2025-05-07”
> “Results First Posted 2026-11-03”

Source: [ClinicalTrials.gov NCT05811247](https://clinicaltrials.gov/study/NCT05811247)

<a id="topic-3.1.2.2-2"></a>

#### Number of locations in the ClinicalTrials.gov record

> “This study has 64 locations”

Source: [ClinicalTrials.gov NCT05811247](https://clinicaltrials.gov/study/NCT05811247)

<a id="topic-3.1.2.2-3"></a>

#### Sites in the United States

> “A total of 64 sites have been identified in the U.S. for LunAIRo (Supplemental Table 1) and 73 sites have been identified in both the U.S. and Canada for SynAIRgy (Supplemental Table 2).”
> “LunAIRo and SynAIRgy were performed in different centers, with the exception of a small number of sites that enrolled for SynAIRgy after the enrollment of LunAIRo was closed. No participant was enrolled in both studies.”

Source: [Taranto-Montemurro et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12490522/)

> “The trial enrolled 660 adult participants from 64 centers in the US.”

Source: [Apnimed LunAIRo topline release (2025)](https://apnimed.com/article/ad109toplinephase3results/)

<a id="topic-3.1.2.2-4"></a>

#### Trial initiation and completion in the prospectus

> “We initiated the LunAIRo and SynAIRgy Phase 3 clinical trials for AD109 in September and November of 2023, respectively.”
> “LunAIRo was conducted in the United States and SynAIRgy was conducted in the United States and Canada.”
> “Both LunAIRo and SynAIRgy trials were completed in 2025 and the OLE trial was completed in 2026.”

Source: [Apnimed prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526328422/apmd_424b4.htm)

<a id="heading-3.1.2.3"></a>

### 3.1.2.3 Study Design

<a id="topic-3.1.2.3-1"></a>

#### Design, randomization, and duration in the protocol

> “The LunAIRo Study (APC-APN-304) is a randomized, double blind, placebo-controlled, 1-year parallel-arm study of AD109 vs placebo in participants with mild to severe OSA who are intolerant of, or currently refuse, PAP.”
> “The first week of dosing will be with a lower dose (run-in) of AD109, or placebo, followed by the target dose taken 50-weeks, then a two-week period without dosing prior to the End of Study visit at 53 weeks.”
> “No interim analysis is planned.”

Source: [Apnimed LunAIRo protocol (2025)](https://cdn.clinicaltrials.gov/large-docs/47/NCT05811247/Prot_000.pdf)

<a id="topic-3.1.2.3-2"></a>

#### Design details in the ClinicalTrials.gov record

| Field | Quoted record |
| --- | --- |
| Official title | “Phase 3 Randomized Double-Blind Placebo-Controlled 1-year Parallel-Arm Study to Compare a Fixed Dose Combination of Aroxybutynin/Atomoxetine (AD109) to Placebo in Obstructive Sleep Apnea (LunAIRo Study)” |
| Other study ID | “APC-APN-304” |
| Allocation | “Randomized” |
| Interventional model | “Parallel Assignment” |
| Masking | “Quadruple (ParticipantCare ProviderInvestigatorOutcomes Assessor)” |
| Enrollment | “Enrollment (Actual) 660” |

Source: [ClinicalTrials.gov NCT05811247](https://clinicaltrials.gov/study/NCT05811247)

<a id="topic-3.1.2.3-3"></a>

#### Stratified randomization and severity strata

> “Randomization is stratified according to baseline AHI4 (<15, 15 to 30, >30) and 8-item PROMIS-Fatigue raw score (<25 vs ≥ 25; a raw score of 25 is equivalent to a T-score of 58.5).”
> “To ensure representative distribution of baseline AHI4 severity, the size of AHI4 strata will be controlled through enrollment limits, with AHI4 <15 representing ∼20–40% of participants, AHI4 15–30 representing ∼20–40% of participants, and AHI4 >30 representing ∼20–40% of participants.”

Source: [Taranto-Montemurro et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12490522/)

> “Our trials were designed to potentially support a broader label indicated for patients across the range of OSA severities by ensuring no more than 40% of the overall study population in each trial could represent mild, moderate or severe patient subgroups.”

Source: [Apnimed prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526328422/apmd_424b4.htm)

<a id="topic-3.1.2.3-4"></a>

#### Polysomnography schedule and central scoring

> “Objective efficacy data are gathered with in-laboratory polysomnograms (PSG) performed at 13, 26, and 51 weeks for the LunAIRo study, and at 4 and 26 weeks for the SynAIRgy study.”
> “The studies are conducted with the support of a PSG scoring center (Sleep Strategies, Ottawa, ON) responsible for centralized PSG scoring blinded to treatment assignment for both screening and outcome assessment and generation of standardized PSG variables.”
> “Each participant's baseline and on-treatment PSGs were evaluated by the same scorer to maintain consistency.”

Source: [Taranto-Montemurro et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12490522/)

<a id="topic-3.1.2.3-5"></a>

#### Ambulatory blood pressure monitoring and blinding

> “Eligible participants in the LunAIRo trial, after V2, will be encouraged to undergo optional 24 h ambulatory blood pressure monitoring (ABPM) before the randomization visit (V3). The ABPM procedure is repeated after 4 weeks of treatment with AD109 or placebo.”
> “All study participants, investigators, site staff, staff at the PSG scoring center, staff at the CRO and sponsor staff are blinded to treatment assignment throughout the studies.”
> “An independent DMC, with expertise in sleep apnea, clinical trials, and biostatistics meets regularly to assess unblinded safety data and make recommendations for both trials.”

Source: [Taranto-Montemurro et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12490522/)

<a id="topic-3.1.2.3-6"></a>

#### Open-label extension after the trial

> “Participants completing either of these studies are eligible for an optional open label extension (OLE) study of AD109 in which safety is assessed for up to an additional year (Supplement Information).”

Source: [Taranto-Montemurro et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12490522/)

Additional sources: [Patel et al. (2024)](https://www.atsjournals.org/doi/10.1164/ajrccm-conference.2024.209.1_MeetingAbstracts.A4551)

<a id="heading-3.1.2.4"></a>

### 3.1.2.4 Eligibility Criteria

<a id="topic-3.1.2.4-1"></a>

#### Inclusion and exclusion criteria in the ClinicalTrials.gov record

> “≥18 years of age at the time of informed consent.”
> “PSG criteria: AHI of >5; ≤ 25% central or mixed apneas; and PLM arousal index ≤15”
> “PROMIS-Fatigue: raw score ≥17”
> “PAP intolerance or current PAP refusal.”
> “BMI between 18.5 and 40 kg/m2 for men, or 42 kg/m2 for women, inclusive.”
> “Insomnia disorder characterized by difficulty initiating or maintaining sleep, or use within the past month of sedative-hypnotics or other medication for the purpose of treating or avoiding insomnia symptoms.”
> “Clinically significant cardiac disease, e.g., ventricular arrhythmia, untreated or unstable coronary artery disease, cardiac failure. Stable atrial arrhythmia is allowed.”

Source: [ClinicalTrials.gov NCT05811247](https://clinicaltrials.gov/study/NCT05811247)

<a id="topic-3.1.2.4-2"></a>

#### Apnea-hypopnea index range and PAP criteria in protocol version 4.0

> “Protocol Version: 4.0 11 June 2025”
> “AHI4 (Hypopneas defined by 4% oxygen desaturation) of >5 and ≤45”
> “PAP failure is defined as no PAP use for ≥3 months prior to randomization, or return/removal of PAP device from the home.”
> “PAP refusal is defined as refusal of PAP after prior positive sleep study, or prior refusal of provider-recommended sleep study due to unwillingness to consider PAP.”

Source: [Apnimed LunAIRo protocol (2025)](https://cdn.clinicaltrials.gov/large-docs/47/NCT05811247/Prot_000.pdf)

<a id="topic-3.1.2.4-3"></a>

#### Apnea-hypopnea index range in the baseline abstract

> “Participants were enrolled over the full range of OSA severity as measured by apnea-hypopnea index with 4% desaturation (AHI4) >5 with no upper limit.”

Source: [Patel et al. (2025a)](https://doi.org/10.1164/ajrccm.2025.211.Abstracts.A6932)

> “Since the mechanism of action should apply, in theory, to all OSA patients, no limit to OSA severity is implemented initially, however caps could be implemented during the trial to ensure that the full range of OSA severities are well-represented in the trials.”

Source: [Taranto-Montemurro et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12490522/)

<a id="topic-3.1.2.4-4"></a>

#### Key exclusion criteria and fatigue threshold in the design paper

> “Current bothersome symptoms of insomnia (difficulty initiating or maintaining sleep, as distinct from unrefreshing sleep or other symptoms attributable to OSA). Participants treated with insomnia can be enrolled if symptoms are controlled”
> “Schizophrenia, schizoaffective disorder, generalized anxiety disorder or bipolar disorder according to DSM-5 criteria”
> “Attempted suicide within 1 year prior to screening, or current suicidal ideation.”
> “Current bothersome symptoms of bladder outlet obstruction including difficulty initiating or maintaining urinary flow, straining, or sensation of incomplete bladder emptying”
> “Blood pressure >145/90 mmHg”
> “Narrow angle glaucoma”
> “Only participants who refuse or are intolerant to PAP and with a raw PROMIS-Fatigue score ≥17 (fatigue level above average of the population; a raw score of 17 is equivalent to a T-score of 50.4) are eligible.”

Source: [Taranto-Montemurro et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12490522/)

<a id="topic-3.1.2.4-5"></a>

#### Disallowed concomitant medications

> “Atomoxetine is metabolized by CYP2D6 and aroxybutynin by CYP3A4, and consequently, strong pharmacologic inhibitors of these metabolic enzymes are not allowed as concomitant therapy.”
> “MAOIs, NRIs, and TCAs,”
> “Strong CYP2D6 inhibitors, and strong CYP3A4 inhibitors”
> “Drugs used exclusively for weight loss”
> “Modafinil, armodafinil, solriamfetol, and pitolisant”
> “Oral anticholinergics, and cholinesterase inhibitors”

Source: [Taranto-Montemurro et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12490522/)

<a id="heading-3.1.2.5"></a>

### 3.1.2.5 Treatment

<a id="topic-3.1.2.5-1"></a>

#### Treatment arms in the ClinicalTrials.gov record

| Arm | Description in the record |
| --- | --- |
| Experimental: AD109 | “Aroxybutynin 2.5 mg/atomoxetine 75 mg tablet, administered orally once daily at bedtime (Weeks 2-51). Week 1 run-in: aroxybutynin 2.5 mg/atomoxetine 37.5 mg tablet.” |
| Placebo Comparator: Placebo | “Matching placebo tablet administered orally once daily at bedtime for 51 weeks, with run-in and target dose matched to active arm packaging.” |

Source: [ClinicalTrials.gov NCT05811247](https://clinicaltrials.gov/study/NCT05811247)

<a id="topic-3.1.2.5-2"></a>

#### No dose reduction, and continued follow-up after discontinuation

> “Dose reduction is not permitted. Dosing is discontinued if the study drug to which the participant is randomized is not tolerated. Note that participants who discontinue dosing are encouraged to continue all other study activities for the full duration of the study.”

Source: [Apnimed LunAIRo protocol (2025)](https://cdn.clinicaltrials.gov/large-docs/47/NCT05811247/Prot_000.pdf)

<a id="topic-3.1.2.5-3"></a>

#### PAP initiation permitted during the trial

> “Participants are not prohibited from initiating PAP during the trial if deemed by the participant's primary care provider to be in the participant's best medical interest. Dosing of AD109 or placebo can continue if PAP is initiated.”

Source: [Taranto-Montemurro et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12490522/)

<a id="topic-3.1.2.5-4"></a>

#### Dispensing of the run-in and target doses

> “The IMP is dispensed as a blister package of 7 run-in dose tablets and a bottle containing 33 target dose tablets.”

Source: [Taranto-Montemurro et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12490522/)

<a id="topic-3.1.2.5-5"></a>

#### Run-in dose and dose reduction in the prospectus

> “A lower dose of AD109 (2.3/37.5mg) was administered during the one-week run-in period; however, dose reduction was not permitted in the Phase 3 trials, to maximize evaluation of efficacy.”

Source: [Apnimed prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526328422/apmd_424b4.htm)

<a id="heading-3.1.2.6"></a>

### 3.1.2.6 Study Outcomes

<a id="heading-3.1.2.6.1"></a>

#### 3.1.2.6.1 Rationale for Using Apnea-Hypopnea Index as the Primary Endpoint

<a id="topic-3.1.2.6.1-1"></a>

##### Primary endpoint: change from baseline in AHI4 at week 26

> “Change from baseline in apnea-hypopnea index based on 4% hypopnea desaturation (AHI4) at week 26”

Source: [Apnimed LunAIRo protocol (2025)](https://cdn.clinicaltrials.gov/large-docs/47/NCT05811247/Prot_000.pdf)

> “AHI, Apnea-Hypopnea Index, is the number of apneas or hypopneas recorded via polysomnography during the study per hour of sleep. Apnea is defined as a cessation of airflow lasting at least 10 seconds, hypopnea as a decrease in airflow by at least 30% from baseline for at least 10 seconds occurring with a drop in oxygen saturation (SpO2) by at least 4%.”

Source: [ClinicalTrials.gov NCT05811247](https://clinicaltrials.gov/study/NCT05811247)

> “The primary efficacy endpoint for both trials is the change from baseline in AHI4 at Week 26.”

Source: [Taranto-Montemurro et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12490522/)

<a id="topic-3.1.2.6.1-2"></a>

##### Protocol amendment 4.0: reordering of the primary and key secondary endpoints, June 2025

> “Protocol Version: 4.0 11 June 2025”
> “Version 4.0 June 11, 2025 As detailed in the following Summary of Changes, Apnimed has introduced modifications to the protocol V3.0 (dated December 11, 2023). Content changes are specified in the table found in Section, 9.6, Appendix 6 with identification of the section in the new protocol.”
> “The order of endpoints, including the primary endpoint and key secondary endpoints, was changed to align with recent regulatory approvals for the treatment of OSA related to obesity.”

Source: [Apnimed LunAIRo protocol (2025)](https://cdn.clinicaltrials.gov/large-docs/47/NCT05811247/Prot_000.pdf)

<a id="topic-3.1.2.6.1-3"></a>

##### Primary endpoint: proportion with at least 50% reduction in AHI4 at six months in the baseline abstract, May 2025, superseded in June 2025

> “The primary efficacy endpoint is the proportion of participants with ≥50% reduction in AHI4 at six months.”

Source: [Patel et al. (2025a)](https://doi.org/10.1164/ajrccm.2025.211.Abstracts.A6932)

<a id="topic-3.1.2.6.1-4"></a>

##### Key secondary and secondary endpoints, in the order tested

> “Change from baseline in ODI3 at week 26”
> “Change from baseline in HB4 (on the natural log scale) at week 26”
> “Proportion of participants with ≥50% reduction in AHI4 at 26 weeks”
> “Change from baseline in PGI-S for fatigue at week 26”
> “Change from baseline in ESS at week 26”

Source: [Apnimed LunAIRo protocol (2025)](https://cdn.clinicaltrials.gov/large-docs/47/NCT05811247/Prot_000.pdf)

<a id="topic-3.1.2.6.1-5"></a>

##### Apnea-hypopnea index as the historical principal biomarker, and hypoxic burden as a complementary metric

> “The primary efficacy endpoint in most OSA trials is the AHI which historically has been the principal biomarker for the disease”
> “Compared to AHI4, that only considers the frequency of obstructive events (events/hour of sleep), the HB4 also incorporates the length and the depth of the apnea/hypopnea-related chronic intermittent hypoxia during sleep [16]. This metric has demonstrated a stronger correlation with cardiovascular mortality than AHI in recent epidemiological cohort analyses [16].”

Source: [Taranto-Montemurro et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12490522/)

<a id="topic-3.1.2.6.1-6"></a>

##### PROMIS-Fatigue as a key secondary endpoint

> “Fatigue is one of the most common patient-reported symptoms in relationship to sleep apnea and disturbed sleep, together with sleepiness [18].”
> “PROMIS-Fatigue may provide increased sensitivity to symptom improvement in OSA [31], particularly in the substantial proportion of OSA patients without EDS [32].”

Source: [Taranto-Montemurro et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12490522/)

<a id="topic-3.1.2.6.1-7"></a>

##### Company interpretation of absolute and relative AHI reductions in a mostly mild-to-moderate population

> “In populations with mild and moderate OSA, meaningful clinical benefits are better reflected by relative reductions in AHI and HB, responder analyses, and shifts to lower disease severity categories, rather than by absolute reductions alone.”
> “To account for this, Phase 3 clinical result analyses for AD109 were based on a prespecified proportional (log-scale) modeling approach, which assumes a consistent relative clinical response across the range of baseline AHI values.”

Source: [Apnimed prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526328422/apmd_424b4.htm)

<a id="topic-3.1.2.6.1-8"></a>

##### FDA pre-NDA feedback on the clinical meaningfulness of the primary endpoint results and the limits of the patient-reported outcomes

> “In connection with the FDA’s review of our top-line Phase 3 data, at the pre-NDA meeting, the FDA provided feedback about the clinical meaningfulness of certain endpoint results, including the primary endpoint and the limitations of the patient-reported outcomes (PROs). The FDA indicated that additional analyses and justification may be needed to support that the data demonstrates a clinically meaningful benefit for the treatment of OSA.”
> “If we are unable to address these concerns to the FDA’s satisfaction, the FDA may determine that the clinical response results from our Phase 3 trials are not clinically meaningful to establish substantial evidence of effectiveness for Oxnimbi in OSA, or that the overall risk-benefit profile of Oxnimbi does not support approval or it may require additional data, analyses or studies to support approval.”

Source: [Apnimed prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526328422/apmd_424b4.htm)

<a id="heading-3.1.2.7"></a>

### 3.1.2.7 Statistical Analysis Description

<a id="heading-3.1.2.7.1"></a>

#### 3.1.2.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.2.7.1-1"></a>

##### Planned sample size and power

> “A total of 640 participants (320/group) will provide >98% power to detect a treatment difference of ≥ 4 points between AD109 and placebo for the change in AHI4.”
> “Based on the observed dropout rates in MARIPOSA, it is assumed that the dropout rate in the placebo group will be 5% and the dropout rate in the AD109 group will be 25%.”
> “With these assumptions, simulation demonstrated that 640 participants (320/group) would provide approximately 90% power to detect a treatment difference of 2.5 points and approximately 95% power to detect a treatment difference of 2.75 points.”

Source: [Taranto-Montemurro et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12490522/)

<a id="topic-3.1.2.7.1-2"></a>

##### Participants randomized

> “Eligible participants (N=660) were randomized (AD109: n=329; PBO: n=331) with 524 (80.0%) completing the study.”

Source: [Patel et al. (2025b)](https://journal.chestnet.org/article/S0012-3692%2825%2905443-1/fulltext)

<a id="topic-3.1.2.7.1-3"></a>

##### Participants analyzed for the primary endpoint, by estimand

| Analysis set | AD109 | Placebo |
| --- | --- | --- |
| “Full Analysis Set (Treatment Policy Estimand)” | “324” | “326” |
| “While-on-Treatment population” | “240” | “293” |

Source: [ClinicalTrials.gov NCT05811247 API record](https://clinicaltrials.gov/api/v2/studies/NCT05811247)

> “In the mITT (AD109: n=240; PBO: n=293)”
> “In the ITT (AD109: n=324; PBO: n=326)”

Source: [Patel et al. (2025b)](https://journal.chestnet.org/article/S0012-3692%2825%2905443-1/fulltext)

<a id="topic-3.1.2.7.1-4"></a>

##### Participants in the safety analysis

> “Adverse Event Data was collected in the Safety Population, which includes all randomized participants who received at least 1 dose of IMP. Participants are summarized based on actual treatment.”

Source: [ClinicalTrials.gov NCT05811247 results](https://clinicaltrials.gov/study/NCT05811247?tab=results)

<a id="heading-3.1.2.7.2"></a>

#### 3.1.2.7.2 Description of Analysis Sets

<a id="topic-3.1.2.7.2-1"></a>

##### Analysis sets in the statistical analysis plan

> “The Full Analysis Set (FAS) consists of all participants who were randomized and received at least 1 dose of investigational medicinal product (IMP). All participants enrolled at Site 1308 will be excluded.”
> “The Modified Intent to Treat (MITT) set for AHI consists of all participants and received at least 1 dose of IMP and had one post baseline on treatment PSG assessment.”
> “The Safety Set (SS) consists of all participants who are randomized and receive at least 1 dose of IMP. Participants will be analyzed according to treatment received.”
> “The Per Protocol Set for AHI4 (PPS-A) consists of all participants in the FAS who completed the study treatment up to week 26 (i.e., visit 6) with at least 70% compliance of taking IMP and have non-missing AHI4 assessment at week 26, without any important protocol violations that could influence the efficacy assessments.”

Source: [Apnimed LunAIRo statistical analysis plan (2025)](https://cdn.clinicaltrials.gov/large-docs/47/NCT05811247/SAP_001.pdf)

<a id="topic-3.1.2.7.2-2"></a>

##### Analysis populations in the ClinicalTrials.gov record

> “The Full Analysis Set (FAS) population included all randomized participants who received at least one dose of investigational medicinal product (IMP). Participants enrolled at Site 1308 were excluded following site termination. The While-On-treatment population was the MITT set and includes participants in the FAS who had at least one post-baseline on-treatment polysomnography (PSG) assessment.”

Source: [ClinicalTrials.gov NCT05811247 API record](https://clinicaltrials.gov/api/v2/studies/NCT05811247)

<a id="topic-3.1.2.7.2-3"></a>

##### Treatment policy estimand for the primary endpoint

> “Treatment condition: investigational treatment with AD109/Placebo regardless of adherence to investigational product and of any changes in background therapy (treatment policy strategy).”
> “Rationale for estimand: The primary estimand aims at reflecting how participants with mild to severe OSA, are treated in clinical practice and considers both safety and efficacy.”
> “Given the anticipated unequal distribution of missing data between the AD109 and Placebo group, missing data will be assumed to be missing not at random (MNAR) and the endpoint will be analyzed using a pattern- mixture model using a control-based approach (further details are provided in the SAP).”

Source: [Apnimed LunAIRo protocol (2025)](https://cdn.clinicaltrials.gov/large-docs/47/NCT05811247/Prot_000.pdf)

<a id="topic-3.1.2.7.2-4"></a>

##### While-on-treatment estimand as a supportive analysis

> “The analysis of the primary efficacy endpoint of change from baseline in AHI4 at week 26 will be repeated using FAS and MITT set and a while on treatment estimand approach under Hypothetical Strategy. For FAS analysis all data collected after a participant has discontinued treatment will be set to missing while for MITT analysis all data collected after a participant has discontinued treatment will be imputed by last available on treatment value.”

Source: [Apnimed LunAIRo statistical analysis plan (2025)](https://cdn.clinicaltrials.gov/large-docs/47/NCT05811247/SAP_001.pdf)

> “The on-treatment estimand, a modified intent-to-treat population, focused on outcomes observed during active treatment exposure and excluded data collected after treatment discontinuation, with missing values imputed using a last-observation-carried-forward approach.”
> “We believe the on treatment estimand provided the most clinically relevant estimate of the clinical response and complemented the primary treatment policy estimand by focusing specifically on the direct clinical response during active medication use, rather than incorporating the effects of treatment discontinuation patterns that might have varied between groups.”

Source: [Apnimed prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526328422/apmd_424b4.htm)

<a id="topic-3.1.2.7.2-5"></a>

##### Statistical model for the primary endpoint

> “The primary analysis methodology will utilize a restricted maximum likelihood (REML) based mixed model for repeated measurements (MMRM) in combination with the Newton Raphson Algorithm. Analyses will include treatment, AHI4 strata, time and the treatment by time interaction as a fixed effects and baseline score as a covariate.”
> “The proportion of participants with ≥50% reduction in AHI4 at Week 26 will be compared between treatment groups using the stratified Cochran-Mantel Haenszel procedure, controlling for randomization strata.”

Source: [Taranto-Montemurro et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12490522/)

<a id="topic-3.1.2.7.2-6"></a>

##### Multiplicity control for the key secondary endpoints

> “Adjustment for multiplicity of the key secondary endpoints will be conducted through a closed testing approach, where each key secondary endpoint will be tested in pre-specified order as follows.”
> “Change from baseline to week 26 in ODI3”
> “Change from baseline to week 26 in HB4”
> “Proportion of patients with ≥50% reduction in AHI4 at week 26”
> “Change from baseline to week 26 in PROMIS-Fatigue”
> “No adjustment for multiplicity will be made for the non-key secondary endpoints or tertiary endpoints or exploratory endpoints.”

Source: [Apnimed LunAIRo statistical analysis plan (2025)](https://cdn.clinicaltrials.gov/large-docs/47/NCT05811247/SAP_001.pdf)

<a id="topic-3.1.2.7.2-7"></a>

##### Week 51 endpoints analyzed as tertiary endpoints

> “Compare efficacy on airway obstruction and OSA symptoms of AD109 vs placebo in participants with mild to severe OSA at 51 weeks”
> “Tertiary Endpoints The following are assessed as change from baseline at week 51 or as specified”
> “The tertiary efficacy endpoints will be analyzed for the FAS and MITT, using the same methods as outlined for the primary endpoint as appropriate.”

Source: [Apnimed LunAIRo statistical analysis plan (2025)](https://cdn.clinicaltrials.gov/large-docs/47/NCT05811247/SAP_001.pdf)

<a id="topic-3.1.2.7.2-8"></a>

##### Pooled phase 3 analysis: estimands and analysis sets

> “Pooled primary efficacy at Week 26 was analyzed in the treatment policy estimand (randomized and received ≥1 treatment dose) with supportive analyses in the on-treatment estimand (≥1 post-baseline on-treatment polysomnogram).”

Source: [Patel et al. (2026a)](https://academic.oup.com/ajrccm/article/212/Supplement_2/aamag286.015/8712277)

<a id="heading-3.1.2.8"></a>

### 3.1.2.8 Results

<a id="heading-3.1.2.8.1"></a>

#### 3.1.2.8.1 Participant Disposition

<a id="topic-3.1.2.8.1-1"></a>

##### Participant flow in the ClinicalTrials.gov record

| Milestone or reason | AD109 | Placebo |
| --- | --- | --- |
| Started | “329” | “331” |
| Completed | “250” | “274” |
| Not completed | “79” | “57” |
| Adverse Event | “12” | “7” |
| Lost to Follow-up | “24” | “20” |
| Other/Not Reported | “5” | “2” |
| Physician Decision | “2” | “7” |
| Site Terminated by Sponsor | “3” | “2” |
| Withdrawal by Subject | “33” | “19” |

Source: [ClinicalTrials.gov NCT05811247 results](https://clinicaltrials.gov/study/NCT05811247?tab=results)

<a id="topic-3.1.2.8.1-2"></a>

##### Study completion

> “Eligible participants (N=660) were randomized (AD109: n=329; PBO: n=331) with 524 (80.0%) completing the study.”

Source: [Patel et al. (2025b)](https://journal.chestnet.org/article/S0012-3692%2825%2905443-1/fulltext)

<a id="topic-3.1.2.8.1-3"></a>

##### Treatment discontinuation due to adverse events and overall treatment discontinuation by month 6 and month 12

> “In LunAIRo, among participants randomized in the main cohort, AE–related discontinuation occurred in 23.7% of participants receiving AD109 and 6.6% receiving placebo by month 6, and remained the most common reason for discontinuation by month 12 (28.6% vs 10.0%), contributing to overall discontinuation rates of 46.5% for AD109 and 25.1% for placebo at month 12.”
> “Importantly, for both trials, AE-related discontinuations occurred predominantly early after treatment initiation, with markedly fewer events later in the treatment period (Figure 32).”

Source: [Apnimed prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526328422/apmd_424b4.htm)

<a id="topic-3.1.2.8.1-4"></a>

##### Treatment discontinuation due to insomnia

> “Insomnia was the main reason for discontinuation in 4.9% of participants in SynAIRgy and 3% of participants in LunAIRo.”

Source: [Apnimed prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526328422/apmd_424b4.htm)

<a id="topic-3.1.2.8.1-5"></a>

##### Pooled phase 3 analysis: study completion and overall treatment discontinuation by week 26

> “Of 1,299 randomized participants (AD109: n = 648; PBO: n = 651), 1,063 (81.8%) completed the trials.”
> “Treatment was discontinued by Week 26 in 227 (35.2%) participants randomized to AD109 and 100 (15.5%) to PBO.”

Source: [Patel et al. (2026b)](https://academic.oup.com/ajrccm/article/212/Supplement_2/aamag286.317/8712356)

> “A total of 1299 participants were randomized 1:1 to receive AD109 (n = 648) or placebo (n = 651); 82.3% (1063/1292) of participants who received treatment completed the trials.”

Source: [Patel et al. (2026a)](https://academic.oup.com/ajrccm/article/212/Supplement_2/aamag286.015/8712277)

<a id="topic-3.1.2.8.1-6"></a>

##### Pooled phase 3 analysis: treatment discontinuation due to adverse events by week 26

> “TEAEs leading to treatment discontinuation by Week 26 was 25.0% (163/653) in participants receiving AD109 and 6.7% (43/646) receiving PBO.”

Source: [Patel et al. (2026a)](https://academic.oup.com/ajrccm/article/212/Supplement_2/aamag286.015/8712277)

<a id="heading-3.1.2.8.2"></a>

#### 3.1.2.8.2 Baseline Characteristics

<a id="topic-3.1.2.8.2-1"></a>

##### Baseline characteristics in the design paper

| Characteristic | LunAIRo (N = 660) |
| --- | --- |
| Age (yrs), mean (SD) | “57 (10)” |
| BMI (kg/m2), mean (SD) | “32.1 (4.8)” |
| Female, n (%) | “303 (46)” |
| Male, n (%) | “357 (54)” |
| Black or African American, n (%) | “113 (17.1)” |
| White, n (%) | “492 (74.5)” |
| Asian, n (%) | “23 (3.5)” |
| Hispanic or Latino, n (%) | “111 (16.8)” |
| AHI4, mean (SD) | “24 (18)” |
| Mild, AHI4 5 to less than 15, n (%) | “248 (37.6)” |
| Moderate, AHI4 15 to less than 30, n (%) | “216 (32.7)” |
| Severe, AHI4 30 or more, n (%) | “196 (29.7)” |
| ODI3, mean (SD) | “32 (19)” |
| HB4, mean (SD) | “55 (68)” |
| PROMIS-Fatigue T-score, mean (SD) | “59 (7)” |
| ESS, mean (SD) | “10.2 (4.8)” |

Source: [Taranto-Montemurro et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12490522/)

<a id="topic-3.1.2.8.2-2"></a>

##### Baseline characteristics of the full analysis set in the ClinicalTrials.gov record

| Characteristic | AD109 (n = 324) | Placebo (n = 326) |
| --- | --- | --- |
| Age, years, mean (SD) | “57.2(10.26)” | “57.4(10.72)” |
| Female | “160” | “138” |
| Male | “164” | “188” |
| Black or African American | “58” | “53” |
| White | “238” | “246” |
| Baseline AHI4 below 15 | “119” | “125” |
| Baseline AHI4 15 to 30 | “109” | “104” |
| Baseline AHI4 above 30 | “96” | “97” |
| Baseline AHI4, events/hr, mean (SD) | “24.03(16.692)” | “24.69(18.735)” |

Source: [ClinicalTrials.gov NCT05811247 results](https://clinicaltrials.gov/study/NCT05811247?tab=results)

<a id="topic-3.1.2.8.2-3"></a>

##### Demographics, AHI4 severity, and symptoms in the baseline abstract

> “Mean (SD) baseline age was 57 (10) years, and mean BMI (SD) was 32.1 (4.8) kg/m2 with 46% female and 54% male participants.”
> “At baseline, mean (SD) AHI4 was 24 (18) with 37%, 33%, and 30% of participants having mild (AHI4 5-<15) moderate (AHI4 15-<30), or severe (AHI4 ≥30) OSA, respectively.”
> “The percentages of participants having a mild, moderate, or severe PGI-S for Fatigue were 24%, 51%, and 21%, respectively. Mean (SD) ESS score was 10.2 (4.8) and mean (SD) HB4 was 55 (68).”

Source: [Patel et al. (2025a)](https://doi.org/10.1164/ajrccm.2025.211.Abstracts.A6932)

<a id="topic-3.1.2.8.2-4"></a>

##### Median baseline AHI4 in the on-treatment set

> “In the mITT (AD109: n=240; PBO: n=293), the AHI4 (events/hr) was reduced from a median (IQR) of 20.4 (11.4–34.1) at baseline to 13.4 (5.6–30.1) at Week 26 with AD109 and from 20.7 (11.1–32.4) at baseline to 20.3 (9.9–35.1) at Week 26 with PBO.”

Source: [Patel et al. (2025b)](https://journal.chestnet.org/article/S0012-3692%2825%2905443-1/fulltext)

<a id="topic-3.1.2.8.2-5"></a>

##### Pooled phase 3 analysis: baseline severity and AHI distribution

> “Baseline OSA severity was mild in 36.2%, moderate in 37.3%, and severe in 26.5% of participants.”

Source: [Patel et al. (2026b)](https://academic.oup.com/ajrccm/article/212/Supplement_2/aamag286.317/8712356)

> “Although patients with higher AHIs were represented, the distribution of AHI at baseline was weighted toward the lower end of the moderate range, with 51% of participants having AHI values below 20 events/hour and 74% falling below 30 events/hour.”

Source: [Apnimed prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526328422/apmd_424b4.htm)

<a id="heading-3.1.2.8.3"></a>

#### 3.1.2.8.3 Efficacy Results

<a id="topic-3.1.2.8.3-1"></a>

##### Week 26 change from baseline in AHI4, treatment policy and while-on-treatment estimands, in the ClinicalTrials.gov record

| Estimand and arm | LS mean change, events/hr | Lower 95% CI | Upper 95% CI |
| --- | --- | --- | --- |
| Treatment policy, AD109 (n = 324) | “-3.88” | “-5.37” | “-2.39” |
| Treatment policy, placebo (n = 326) | “0.21” | “-1.24” | “1.65” |
| While-on-treatment, AD109 (n = 240) | “-5.83” | “-7.51” | “-4.15” |
| While-on-treatment, placebo (n = 293) | “-0.02” | “-1.55” | “1.50” |

Source: [ClinicalTrials.gov NCT05811247 API record](https://clinicaltrials.gov/api/v2/studies/NCT05811247)

| Comparison | LS mean difference | Lower 95% CI | Upper 95% CI | p-value |
| --- | --- | --- | --- | --- |
| “Analyses were conducted under the Treatment Policy estimand” | “-4.08” | “-6.14” | “-2.03” | “<0.001” |
| “Analyses were conducted under the While-on-Treatment Estimand” | “-5.81” | “-8.07” | “-3.55” | “<0.0001” |

Source: [ClinicalTrials.gov NCT05811247 API record](https://clinicaltrials.gov/api/v2/studies/NCT05811247)

<a id="topic-3.1.2.8.3-2"></a>

##### Week 26 change in AHI4, treatment policy estimand (ITT set)

> “In the ITT (AD109: n=324; PBO: n=326), AD109 significantly reduced AHI4 by −3.9 (−5.4, −2.4) vs 0.2 (−1.2, 1.7) for PBO (p<0.001).”

Source: [Patel et al. (2025b)](https://journal.chestnet.org/article/S0012-3692%2825%2905443-1/fulltext)

> “LunAIRo: Treatment Policy Estimand: AD109 significantly reduced mean AHI by 3.9 events/hr vs placebo (+0.2 events/hr; placebo-adjusted: 4.1 events/hr; p<0.001); On Treatment Estimand: AD109 significantly reduced mean AHI by 5.8 events/hr vs placebo (0 events/hr; placebo-adjusted: 5.8 events/hr; p<0.0001).”

Source: [Apnimed prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526328422/apmd_424b4.htm)

<a id="topic-3.1.2.8.3-3"></a>

##### Week 26 relative change in AHI4, treatment policy and on-treatment estimands

> “LunAIRo: Treatment Policy Estimand: AD109 significantly reduced AHI by 33.7% vs placebo (7.3%; p<0.0001); On Treatment Estimand: AD109 significantly reduced AHI by 46.8% vs placebo (6.8%; p<0.0001)”
> “Data are least-squares (LS) mean estimated relative change from baseline from mixed model for repeated measurements (MMRM) analysis. Error bars represent 95% confidence intervals. Analysis was performed on the log scale and back transformed.”

Source: [Apnimed prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526328422/apmd_424b4.htm)

<a id="topic-3.1.2.8.3-4"></a>

##### Week 26 and week 51 change in AHI4, on-treatment estimand (mITT set)

> “In the mITT, AD109 significantly reduced AHI4 (LS mean [95% CI]) at Week 26 by −5.8 (−7.5, −4.2) vs −0.0 (−1.6, 1.5) with PBO (p<0.0001), representing 46.8% improvement at Week 26 (vs 6.8% with PBO; p<0.001) and 43.5% improvement at Week 51 (vs 13.2% with PBO; p<0.001).”

Source: [Patel et al. (2025b)](https://journal.chestnet.org/article/S0012-3692%2825%2905443-1/fulltext)

> “In the mITT population, AD109 achieved a significant reduction in mean AHI from baseline (46.8%, p<0.001) compared to placebo (6.8%, p<0.001) at 26 weeks.”

Source: [Apnimed CHEST 2025 release (2025)](https://apnimed.com/article/apnimed-to-present-additional-phase-3-data-for-ad109-an-investigational-oral-pill-for-obstructive-sleep-apnea-at-chest-2025-annual-meeting/)

<a id="topic-3.1.2.8.3-5"></a>

##### Week 26 and week 51 AHI reduction as reported in the company release

> “Participants treated with AD109 achieved a mean reduction in AHI of 46.8% from baseline at week 26 (vs 6.8% with placebo; p<0.001). The reduction in AHI remained significant at end of study (week 51, p<0.001).”

Source: [Apnimed LunAIRo topline release (2025)](https://apnimed.com/article/ad109toplinephase3results/)

<a id="topic-3.1.2.8.3-6"></a>

##### Attenuation of the treatment policy estimate at week 51

> “The smaller clinical response observed at week 51 in LunAIRo primarily reflects higher treatment discontinuation in the AD109 group and the conservative handling of missing data using control-based imputation. Among participants who remained on treatment, clinical responses were maintained over time.”

Source: [Apnimed prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526328422/apmd_424b4.htm)

<a id="topic-3.1.2.8.3-7"></a>

##### Key secondary endpoint: week 26 ODI3, on-treatment estimand (mITT set)

> “In the mITT, AD109 significantly improved select secondary endpoints at Week 26, including change in oxygen desaturation index – ODI3 (LS mean [95% CI]; −7.5 [−9.4, −5.7] vs −0.1 [−1.7, 1.6]; events/hr; p<0.0001) and relative change in hypoxic burden – HB4 (58.2% vs 13.8%; p<0.0001).”

Source: [Patel et al. (2025b)](https://journal.chestnet.org/article/S0012-3692%2825%2905443-1/fulltext)

<a id="topic-3.1.2.8.3-8"></a>

##### Key secondary endpoint: week 26 ODI3, treatment policy and on-treatment estimands

> “LunAIRo: Treatment Policy Estimand: AD109 showed a significant mean relative reduction from significantly reduced ODI3 of 29.5% (5.3 events/hr) vs placebo (3.5%; +0.2 events/hr; p<0.0001) at week 26; On Treatment Estimand: AD109 significantly reduced ODI3 of 40.3% (7.5 events/hr) vs placebo (3.3%; -0.1 events/hr; p<0.0001) at week 26.”
> “For treatment Policy Estimand: AD109 reduced LS means ODI3 by 6.3 events/ hr vs placebo (0.7 events/hr; p<0.0001); On Treatment Estimand: AD109 reduced ODI3 by 8.3 events/hr vs placebo (0.3 events/hr; p<0.0001).”

Source: [Apnimed prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526328422/apmd_424b4.htm)

<a id="topic-3.1.2.8.3-9"></a>

##### Key secondary endpoint: week 26 hypoxic burden, treatment policy and on-treatment estimands

> “LunAIRo: Treatment Policy Estimand: AD109 significantly reduced mean HB by 37.4% vs placebo (10.0%; p<0.001); On Treatment Estimand: AD109 significantly reduced mean HB by 58.2% vs placebo (13.8%; p<0.0001).”

Source: [Apnimed prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526328422/apmd_424b4.htm)

<a id="topic-3.1.2.8.3-10"></a>

##### Key secondary endpoint: at least 50% reduction in AHI4 at week 26, on-treatment estimand (mITT set)

> “AD109 significantly reduced AHI4 by ≥50% at Week 26 in 38.3% of participants (vs 15.4% in PBO; p<0.0001) in the mITT.”

Source: [Patel et al. (2025b)](https://journal.chestnet.org/article/S0012-3692%2825%2905443-1/fulltext)

<a id="topic-3.1.2.8.3-11"></a>

##### Key secondary endpoint: at least 50% reduction in AHI at week 26, treatment policy and on-treatment estimands

> “LunAIRo: Treatment Policy Estimand: AD109 significantly reduced AHI≥50% in 28.5% of participants vs placebo (16.0%; p<0.001); On Treatment Estimand: AD109 significantly reduced AHI ≥50% in 38.3% of participants vs placebo (15.4%; p<0.0001).”

Source: [Apnimed prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526328422/apmd_424b4.htm)

<a id="topic-3.1.2.8.3-12"></a>

##### Severity category improvement and disease control at week 26, on-treatment estimand (mITT set)

> “45.0% of participants treated with AD109 showed a reduction in OSA disease severity category”
> “22.9% of participants treated with AD109 achieved complete OSA disease control (defined as AHI <5 events/hour)”

Source: [Apnimed CHEST 2025 release (2025)](https://apnimed.com/article/apnimed-to-present-additional-phase-3-data-for-ad109-an-investigational-oral-pill-for-obstructive-sleep-apnea-at-chest-2025-annual-meeting/)

<a id="topic-3.1.2.8.3-13"></a>

##### Severity category improvement and disease control at weeks 26 and 51, as reported in the company release

> “AD109 improved OSA disease severity for 45.0% of participants at week 26, and 47.5% at week 51”
> “AD109 achieved OSA complete disease control (AHI<5) for 22.9% of participants at week 26, and 22.5% at week 51”

Source: [Apnimed LunAIRo topline release (2025)](https://apnimed.com/article/ad109toplinephase3results/)

<a id="topic-3.1.2.8.3-14"></a>

##### Apnea index and hypopnea index at week 26, estimand not stated

> “Similarly, in LunAIRo, the mean relative reduction of apnea index was 67.1% (vs 2.8% reduction on placebo), while the mean hypopnea index saw a 37.8% reduction (vs 3.1% on placebo).”

Source: [Apnimed prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526328422/apmd_424b4.htm)

<a id="topic-3.1.2.8.3-15"></a>

##### Pooled phase 3 analysis: week 26 change in AHI4, treatment policy estimand

> “In the treatment policy estimand (AD109: n = 626; PBO: n = 639), AD109 reduced AHI4 (LS mean [95% CI]; events/hr) by − 3.7 [−4.8, −2.5] vs 0.4 [−0.8, 1.5] (p < 0.0001), representing a model-estimated 39.3% reduction from baseline (vs 12.6% with PBO; p < 0.0001).”

Source: [Patel et al. (2026b)](https://academic.oup.com/ajrccm/article/212/Supplement_2/aamag286.317/8712356)

> “In the treatment policy estimand (AD109: n = 626; PBO: n = 639), AD109 reduced AHI4 (LS mean difference [95%CI]: −4.0 [−5.6, −2.5]; p < 0.0001), representing a model-estimated 39.3% reduction from baseline (vs 12.6% [PBO]; p < 0.0001).”

Source: [Patel et al. (2026a)](https://academic.oup.com/ajrccm/article/212/Supplement_2/aamag286.015/8712277)

<a id="topic-3.1.2.8.3-16"></a>

##### Pooled phase 3 analysis: week 26 change in AHI4, on-treatment estimand

> “In the on-treatment estimand (AD109: n = 500; PBO: n = 589), AD109 reduced AHI4 (−6.2 [−7.8, −4.6]; p < 0.0001), representing a model-estimated 51.6% reduction from baseline (vs 13.3% [PBO]; p < 0.0001).”

Source: [Patel et al. (2026a)](https://academic.oup.com/ajrccm/article/212/Supplement_2/aamag286.015/8712277)

<a id="topic-3.1.2.8.3-17"></a>

##### Pooled phase 3 analysis: responders, disease control, and hypoxic burden, treatment policy estimand

> “AD109 reduced AHI4 by ≥ 50% in 28.3% of participants (vs 17.7% with PBO; p < 0.0001); a higher proportion of participants receiving AD109 achieved disease control (AHI4<5; p < 0.0001). AD109 exhibited greater relative reduction in hypoxic burden (41.6% vs 9.9%; p < 0.0001).”

Source: [Patel et al. (2026b)](https://academic.oup.com/ajrccm/article/212/Supplement_2/aamag286.317/8712356)

<a id="topic-3.1.2.8.3-18"></a>

##### Pooled phase 3 analysis: responders, disease control, and hypoxic burden, reported after the on-treatment estimand results

> “39.0% achieved an AHI4 reduction ≥50% with AD109 (vs 18.8% [PBO]; p < 0.0001). More participants receiving AD109 (22.6%) achieved OSA disease control (AHI4<5; vs 8.3% [PBO]; p < 0.0001). AD109 reduced hypoxic burden by 59.6% from baseline (vs 14.9% [PBO]; p < 0.0001).”

Source: [Patel et al. (2026a)](https://academic.oup.com/ajrccm/article/212/Supplement_2/aamag286.015/8712277)

<a id="topic-3.1.2.8.3-19"></a>

##### Pooled phase 3 analysis: severity category improvement and disease control, treatment policy and on-treatment estimands

> “In this analysis, AD109 improved OSA disease severity for 48% of participants at week 26. The proportion of participants achieving complete OSA disease control (AHI<5) was also assessed. AD109 achieved OSA disease control (AHI <5) for 22.6% of participants at 26 weeks (p<0.0001 for both treatment policy and on-treatment estimands).”
> “39% of patients achieved a ≥50% reduction in AHI and 23% achieving a ≥70% reduction (on treatment).”

Source: [Apnimed prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526328422/apmd_424b4.htm)

<a id="topic-3.1.2.8.3-20"></a>

##### Pooled phase 3 analysis: week 26 AHI adjusted for changes in REM sleep and BMI, on-treatment estimand

| Model, LS mean (95% CI), events/h at week 26 | AD109 (n = 500) | Placebo (n = 589) | Estimated treatment difference (95% CI) | p-value |
| --- | --- | --- | --- | --- |
| Primary model for change from baseline in AHI | “–6.1 (–7.3 to –4.9)” | “0.1 (–1.0 to 1.2)” | “–6.2 (–7.8 to –4.6)” | “<0.0001” |
| Model adjusted for change in proportion of REM sleep | “–5.7 (–7.1 to –4.2)” | “0.2 (–1.1 to 1.4)” | “–5.9 (–7.9 to –3.8)” | “<0.0001” |
| Model adjusted for change in BMI | “–5.1 (–6.4 to -3.8)” | “–0.2 (–1.4 to 0.9)” | “–4.9 (–6.6 to –3.1)” | “<0.0001” |

Source: [Apnimed prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526328422/apmd_424b4.htm)

<a id="topic-3.1.2.8.3-21"></a>

##### Pooled phase 3 analysis: snoring frequency at week 26 in participants with an on-treatment polysomnogram

> “Of these, N = 189 (AD109) and N = 281 (Placebo) participants met baseline snoring criteria for inclusion.”
> “AD109 reduced the proportion of breaths with snoring by 22.3 [19.1, 25.5] % (Estimate [95%CI]) vs a placebo reduction of 10.0 [7.4,12.6]% (difference: -12.3 [-16.4, -8.2] %, p < 0.001), Figure 1A. A majority (60.8%) of participants treated with AD109 exhibited a ≥ 50% reduction in the proportion of breaths with snoring, compared to 32.0% of those on placebo (p < 0.001, Figure1B).”

Source: [Gell et al. (2026b)](https://academic.oup.com/ajrccm/article/doi/10.1093/ajrccm/aamag162.6398/8686957)

> “Snoring, an important symptom affecting OSA patients and their bed partners and driving patients to seek clinical evaluation, was analyzed as a prespecified exploratory endpoint in both the LunAIRo and SynAIRgy Phase 3 trials and in a pooled analysis of the on treatment estimand. Analyses were conducted using observed data only, without LOCF imputation.”

Source: [Apnimed prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526328422/apmd_424b4.htm)

<a id="topic-3.1.2.8.3-22"></a>

##### Pooled phase 3 analysis: modeled cardiovascular risk reduction from hypoxic burden, treatment policy and on-treatment estimands

> “Across the pooled LunAIRo and SynAIRgy trials, mean HB reduction with AD109 was 41.6% (95% CI: 34.7-47.8) in the treatment policy estimand and 59.6% (95% CI: 54.3-64.6) in the on treatment estimand, which corresponded to a predicted reduction in the risk of CV events or all-cause mortality of 11.9% (95% CI: 4.7-18.5) and 19.2% (95% CI: 8.2-28.8), respectively.”
> “Cohort-specific HR estimates were pooled using an inverse-variance weighted random-effects meta-analysis and used to estimate risk reduction associated with the observed HB reduction at Week 26 in AD109-treated participants”

Source: [Azarbarzin et al. (2026)](https://academic.oup.com/ajrccm/article/doi/10.1093/ajrccm/aamag162.6399/8686692)

> “These estimates are based on epidemiologic associations and are intended to provide clinical context for the observed improvements in HB and do not represent direct clinical outcomes measured in the Phase 3 trials.”

Source: [Apnimed prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526328422/apmd_424b4.htm)

<a id="topic-3.1.2.8.3-23"></a>

##### Pooled phase 3 analysis: AHI response with concomitant GLP-1 receptor agonists, estimand not stated

> “Across these trials, the effects of AD109 on AHI reduction were directionally similar in participants receiving GLP-1 therapy and those not receiving GLP-1 therapy, suggesting that the treatment effect of AD109 was additive to GLP-1 use in participants on stable doses.”

Source: [Apnimed prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526328422/apmd_424b4.htm)

<a id="topic-3.1.2.8.3-24"></a>

##### Pooled phase 3 analysis: body weight change with concomitant GLP-1 receptor agonists for diabetes, exploratory, estimand not stated

> “One-hundred and six participants were enrolled in the phase 3 trials taking a GLP-1 RA for diabetes (PBO+GLP-1 RA: n=48; AD109+GLP-1 RA: n=58).”
> “In participants receiving a GLP-1 RA with baseline BMI ≥35, AD109 reduced weight by 5.5% (vs PBO: 0.9%, P=0.02) and 11.5% (vs PBO: 3.8%, P=0.04) at Week 26 and Week 51, respectively.”
> “Participants not receiving GLP-1 RA (n=979) showed smaller weight reductions across BMI classes; in participants with BMI ≥35, AD109 reduced weight by 1.4% (vs PBO: 0.2%, P=0.002) and 2.8% (vs PBO: 1.4%, P=0.19) at Week 26 and Week 51, respectively.”

Source: [Strollo et al. (2026a)](https://academic.oup.com/sleep/article/49/Supplement_1/A261/8673726)

<a id="heading-3.1.2.8.4"></a>

#### 3.1.2.8.4 Health-related Quality of Life and Patient-reported Outcomes

<a id="topic-3.1.2.8.4-1"></a>

##### Key secondary endpoint: week 26 PROMIS-Fatigue T-score, on-treatment estimand (mITT set)

> “In the mITT, the change from baseline PROMIS-Fatigue T-score (LS mean [95% CI]) at Week 26 was −6.5 (−7.3, −5.6) with AD109 vs −6.9 (−7.7, −6.1) with PBO (p=0.49).”

Source: [Patel et al. (2025b)](https://journal.chestnet.org/article/S0012-3692%2825%2905443-1/fulltext)

<a id="topic-3.1.2.8.4-2"></a>

##### Week 26 PROMIS-Fatigue and PROMIS-Sleep Impairment, treatment policy and on-treatment estimands

> “LunAIRo: Treatment Policy Estimand: AD109 did not significantly reduce PROMIS Fatigue T-score; On Treatment Estimand: AD109 did not significantly reduce PROMIS Fatigue T-score”
> “No treatment effect was observed on PROMIS Sleep Impairment.”

Source: [Apnimed prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526328422/apmd_424b4.htm)

<a id="topic-3.1.2.8.4-3"></a>

##### Pooled phase 3 analysis: week 26 PROMIS-Fatigue, PROMIS-Sleep Impairment, and ESS, on-treatment estimand

> “In the pooled analysis of PROs utilizing the on-treatment estimand (AD109: n=500; PBO: n=589), results (LS mean difference [SE]) numerically favored AD109 over PBO in PROMIS-F T-score (−0.48 [0.43]; P=0.27), PROMIS-SI T-score (−0.54 [0.48]; P=0.26) and ESS (= −0.18 [0.21]; P=0.4) at Week 26.”
> “A higher proportion of participants receiving AD109 achieved ≥3 point improvement in ESS at Week 26 relative to PBO (48.2% vs 41.6%; P=0.018).”

Source: [Strollo et al. (2026b)](https://academic.oup.com/sleep/article/49/Supplement_1/A302/8674486)

<a id="topic-3.1.2.8.4-4"></a>

##### Pooled phase 3 analysis: participants with baseline ESS of 10 or more, on-treatment estimand

> “In participants with baseline excessive daytime sleepiness (AD109: n=280; PBO: n=294), AD109 significantly improved PROMIS-F and PROMIS-SI T-scores (LS mean±SE) at Week 26 by −8.8±0.4 and −9.9±0.5 points, respectively (vs −7.2±0.4 and −8.2±0.5 with PBO; P=0.007 and P=0.01). Similarly, AD109 significantly improved ESS (LS mean ± SE) at Week 26 by −4.5±0.2 points in participants having baseline excessive daytime sleepiness (vs −3.9±0.2 with PBO; P=0.04).”

Source: [Strollo et al. (2026b)](https://academic.oup.com/sleep/article/49/Supplement_1/A302/8674486)

<a id="topic-3.1.2.8.4-5"></a>

##### Pooled phase 3 analysis: participants with baseline ESS of 10 or more, treatment policy estimand

> “In participants with baseline excessive daytime sleepiness (ESS≥10; AD109: n = 348; PBO: n = 316), AD109 improved PROMIS-Fatigue and PROMIS-Sleep Impairment T-scores (p = 0.044 and p = 0.048, respectively).”

Source: [Patel et al. (2026b)](https://academic.oup.com/ajrccm/article/212/Supplement_2/aamag286.317/8712356)

<a id="topic-3.1.2.8.4-6"></a>

##### Pooled phase 3 analysis: per-protocol set, treatment policy estimand dataset

> “The pooled treatment policy estimand dataset, for LS mean change from baseline at week 26, showed improvements in the PROMIS Fatigue (-7.7 on AD109 vs –6.6 on placebo, p=0.035) and PROMIS Sleep Impairment (-8.5 on AD109 vs –7.3 on placebo, p=0.017) regardless of baseline symptoms.”

Source: [Apnimed prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526328422/apmd_424b4.htm)

<a id="topic-3.1.2.8.4-7"></a>

##### Pooled phase 3 analysis: association between baseline AHI and baseline patient-reported outcomes

> “The Pearson correlation coefficients (r ≈ 0 for both analyses) indicate no meaningful linear association between baseline AHI and either patient reported outcome.”

Source: [Apnimed prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526328422/apmd_424b4.htm)

<a id="heading-3.1.2.8.5"></a>

#### 3.1.2.8.5 Safety Results

<a id="topic-3.1.2.8.5-1"></a>

##### Overall adverse events and most common adverse events

> “Adverse events (AEs) were predominantly mild, with ≥1 AE reported by 272 (82.9%) participants with AD109 and 223 (68.2%) with PBO. The most common AEs with AD109 (≥5% of participants and >PBO) were dry mouth, insomnia, nausea, urinary hesitation, somnolence, headache, dyspepsia, urinary tract infection, constipation, and dizziness. No treatment-related serious AEs were identified.”

Source: [Patel et al. (2025b)](https://journal.chestnet.org/article/S0012-3692%2825%2905443-1/fulltext)

<a id="topic-3.1.2.8.5-2"></a>

##### Adverse event reporting period and definition

> “from enrollment until the end of follow-up, up to 53 weeks”
> “Adverse events are reported as treatment-emergent adverse events (TEAEs), defined as events with onset after the first dose of study drug and up to 7 days after the last dose.”

Source: [ClinicalTrials.gov NCT05811247 results](https://clinicaltrials.gov/study/NCT05811247?tab=results)

<a id="topic-3.1.2.8.5-3"></a>

##### Non-serious adverse events in at least 5% of participants in either arm

| Adverse event | AD109, affected / at risk (%) | Placebo, affected / at risk (%) |
| --- | --- | --- |
| Total | “220/328 (67.07%)” | “122/327 (37.31%)” |
| Dry mouth | “130/328 (39.63%)” | “31/327 (9.48%)” |
| Middle insomnia | “44/328 (13.41%)” | “13/327 (3.98%)” |
| Nausea | “43/328 (13.11%)” | “7/327 (2.14%)” |
| Initial insomnia | “32/328 (9.76%)” | “12/327 (3.67%)” |
| Urinary hesitation | “27/328 (8.23%)” | “2/327 (0.61%)” |
| Somnolence | “24/328 (7.32%)” | “12/327 (3.67%)” |
| Headache | “22/328 (6.71%)” | “23/327 (7.03%)” |
| Dyspepsia | “20/328 (6.10%)” | “7/327 (2.14%)” |
| Urinary tract infection | “20/328 (6.10%)” | “10/327 (3.06%)” |
| Constipation | “19/328 (5.79%)” | “8/327 (2.45%)” |
| Upper respiratory tract infection | “19/328 (5.79%)” | “26/327 (7.95%)” |
| Dizziness | “17/328 (5.18%)” | “6/327 (1.83%)” |
| COVID-19 | “14/328 (4.27%)” | “25/327 (7.65%)” |

Source: [ClinicalTrials.gov NCT05811247 results](https://clinicaltrials.gov/study/NCT05811247?tab=results)

<a id="topic-3.1.2.8.5-4"></a>

##### Serious adverse events and deaths

| Event | AD109, affected / at risk (%) | Placebo, affected / at risk (%) |
| --- | --- | --- |
| All-cause mortality | “0/328 (0.00%)” | “0/327 (0.00%)” |
| Any serious adverse event | “5/328 (1.52%)” | “10/327 (3.06%)” |
| Acute myocardial infarction | “0/328 (0.00%)” | “1/327 (0.31%)” |
| Aortic dissection | “1/328 (0.30%)” | “0/327 (0.00%)” |
| Intracranial aneurysm | “1/328 (0.30%)” | “0/327 (0.00%)” |
| Ischaemic stroke | “0/328 (0.00%)” | “1/327 (0.31%)” |
| Suicide attempt | “0/328 (0.00%)” | “1/327 (0.31%)” |

Source: [ClinicalTrials.gov NCT05811247 results](https://clinicaltrials.gov/study/NCT05811247?tab=results)

<a id="topic-3.1.2.8.5-5"></a>

##### Relatedness of serious adverse events as classified in the ClinicalTrials.gov record

> “AE was classified as moderate and not related to study intervention”
> “AE was classified as severe and unlikely related to study intervention”
> “AE was classified as severe and possibly related to study intervention”

Source: [ClinicalTrials.gov NCT05811247 results](https://clinicaltrials.gov/study/NCT05811247?tab=results)

<a id="topic-3.1.2.8.5-6"></a>

##### Absence of serious adverse events related to AD109

> “No serious adverse events related to AD109 were reported in the LunAIRo trial.”

Source: [Apnimed LunAIRo topline release (2025)](https://apnimed.com/article/ad109toplinephase3results/)

<a id="topic-3.1.2.8.5-7"></a>

##### Ambulatory blood pressure and heart rate at week 4

> “The LunAIRo study included an assessment of 24-hour monitoring of ambulatory blood pressure at week 4, demonstrating small changes in mean arterial pressure (1.9 mmHg) and heart rate (4.6 bpm).”

Source: [Apnimed prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526328422/apmd_424b4.htm)

<a id="topic-3.1.2.8.5-8"></a>

##### Change in BMI at week 51

> “Change in BMI in LunAIRo at 51 weeks was also small: median (IQR) change was -0.2 (-1.4 to 0.8) with AD109 and -0.1 (-0.9 to 0.7) with placebo.”

Source: [Apnimed prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526328422/apmd_424b4.htm)

<a id="topic-3.1.2.8.5-9"></a>

##### Pooled phase 3 analysis: overall and most common treatment-emergent adverse events

> “TEAEs were predominantly mild, with ≥1 TEAE reported by 500 (76.6%) participants on AD109 and 370 (57.3%) on PBO. The most common TEAEs were dry mouth, insomnia, nausea, urinary hesitation, somnolence, and constipation. No AD109-related serious TEAEs were identified.”

Source: [Patel et al. (2026a)](https://academic.oup.com/ajrccm/article/212/Supplement_2/aamag286.015/8712277)

<a id="topic-3.1.2.8.5-10"></a>

##### Pooled phase 3 analysis: major adverse cardiovascular events

> “Across the pooled tolerability dataset, no (n=0) MACE were reported in participants receiving AD109. Five (n=5) MACE were reported in participants receiving placebo.”
> “The Phase 3 trials were not designed or powered to assess cardiovascular outcomes; however, no major adverse cardiovascular events (MACE) were observed in the AD109 group during one year of follow-up, compared with five events in the placebo group.”

Source: [Apnimed prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526328422/apmd_424b4.htm)

<a id="topic-3.1.2.8.5-11"></a>

##### Pooled phase 3 analysis: heart rate and blood pressure, safety analysis set

| Measure | AD109 (n = 653) | Placebo (n = 646) | p-value |
| --- | --- | --- | --- |
| Heart rate, beats/min, mean change (SD) to week 26, evening pre-PSG | “2.0 (11.2)” | “-0.7 (10.0)” | Not reported |
| Heart rate, beats/min, mean change (SD) to week 26, morning post-PSG | “3.4 (9.5)” | “-0.7 (9.4)” | Not reported |
| Heart rate ≥100 beats/min on study, n (%) | “48 (7.4)” | “28 (4.3)” | “0.021” |
| Systolic blood pressure ≥140 mm Hg on study, n (%) | “175 (26.8)” | “168 (26.0)” | “0.760” |
| Diastolic blood pressure ≥90 mm Hg on study, n (%) | “146 (22.4)” | “131 (20.3)” | “0.368” |

Source: [Apnimed prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526328422/apmd_424b4.htm)

<a id="topic-3.1.2.8.5-12"></a>

##### Phase 3 program: onset, duration, and severity of insomnia

> “The median time of first onset for insomnia was a median (IQR) of 3 days (1 to 12) and the duration of the first event was 16 (6 to 67) days. Insomnia was mild for 79.2% of cases, moderate for 17.4% and severe for 3.4%.”

Source: [Apnimed prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526328422/apmd_424b4.htm)

<a id="heading-3.1.2.9"></a>

### 3.1.2.9 Study Limitations

<a id="topic-3.1.2.9-1"></a>

#### Summary

- Publication status: results are available from a congress abstract, the registry results (first posted 2026-11-03), company releases, and the prospectus; the 2026 editorial on SynAIRgy described LunAIRo results as forthcoming.
- Design: placebo-controlled for 51 weeks, with the primary endpoint at week 26; week 51 efficacy was analyzed as a tertiary endpoint. No active comparator was used, dose reduction was not permitted, and all 64 sites were in the United States.
- Population: adults intolerant of or refusing PAP with a PROMIS-Fatigue raw score of at least 17, and a BMI cap of 40 (men) or 42 (women) kg/m2. Exclusions included bothersome insomnia, clinically significant cardiac disease, blood pressure above 145/90 mmHg, specified psychiatric disorders, and narrow angle glaucoma.
- Eligibility AHI differs by source: protocol version 4.0 states AHI4 of more than 5 and up to 45, the registry states AHI of more than 5, and the baseline abstract states no upper limit. The design paper states caps could be added during the trial.
- Severity mix: in the pooled phase 3 population, 51% had AHI below 20 events/h and 74% below 30, per the prospectus.
- Endpoint change: the 2025 baseline abstract named the proportion with at least 50% AHI4 reduction at six months as the primary endpoint. Protocol amendment 4.0 (June 2025) reordered the primary and key secondary endpoints “to align with recent regulatory approvals for the treatment of OSA related to obesity”, after the registry's actual primary completion date (2025-05-07).
- Estimands and missing data: the treatment policy estimand assumed data missing not at random with control-based imputation. The on-treatment estimand excluded data after treatment discontinuation with last observation carried forward and included 240 participants on AD109 and 293 on placebo, against 324 and 326 in the full analysis set. The company states the on-treatment estimand gave the most clinically relevant estimate, and attributes the smaller week 51 response to higher discontinuation with AD109 and control-based imputation. The topline release reported the on-treatment relative reduction (46.8%).
- Analysis-set exclusions: participants at site 1308 were excluded from the full analysis set after the site was terminated.
- Discontinuation: treatment discontinuation due to adverse events was 23.7% with AD109 and 6.6% with placebo by month 6 and 28.6% and 10.0% by month 12; overall treatment discontinuation at month 12 was 46.5% and 25.1% (prospectus, main cohort). In the registry, 250 of 329 participants on AD109 and 274 of 331 on placebo completed the study.
- Patient-reported outcomes: AD109 did not significantly reduce the PROMIS-Fatigue T-score under either estimand, and no treatment effect was observed on PROMIS Sleep Impairment.
- Pooled analyses: Patel et al. (2026a) reports the pooled 39.0% versus 18.8% responder result without an estimand label, while the prospectus labels the pooled 39% as on treatment. The prospectus states the phase 3 trials were not designed or powered to assess cardiovascular outcomes.
- Clinical meaningfulness: at the pre-NDA meeting the FDA gave feedback on the clinical meaningfulness of the primary endpoint results and the limitations of the PROs, and indicated additional analyses and justification may be needed.
- Sponsor: the prospectus describes LunAIRo as a trial the company initiated.

Source: [Apnimed LunAIRo protocol (2025)](https://cdn.clinicaltrials.gov/large-docs/47/NCT05811247/Prot_000.pdf); [Apnimed LunAIRo statistical analysis plan (2025)](https://cdn.clinicaltrials.gov/large-docs/47/NCT05811247/SAP_001.pdf); [ClinicalTrials.gov NCT05811247](https://clinicaltrials.gov/study/NCT05811247); [ClinicalTrials.gov NCT05811247 results](https://clinicaltrials.gov/study/NCT05811247?tab=results); [ClinicalTrials.gov NCT05811247 API record](https://clinicaltrials.gov/api/v2/studies/NCT05811247); [Taranto-Montemurro et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12490522/); [Patel et al. (2025a)](https://doi.org/10.1164/ajrccm.2025.211.Abstracts.A6932); [Patel et al. (2025b)](https://journal.chestnet.org/article/S0012-3692%2825%2905443-1/fulltext); [Patel et al. (2026a)](https://academic.oup.com/ajrccm/article/212/Supplement_2/aamag286.015/8712277); [Apnimed LunAIRo topline release (2025)](https://apnimed.com/article/ad109toplinephase3results/); [Apnimed prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526328422/apmd_424b4.htm); [Mehra and Mokhlesi (2026)](https://academic.oup.com/ajrccm/article/212/7/1427/8679096)

## Related pages
- [AD109 (aroxybutynin-atomoxetine): Obstructive sleep apnea](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Terms and abbreviations](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/terms-and-abbreviations.md)
- [AD109 (aroxybutynin-atomoxetine): Obstructive sleep apnea](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/executive-summary) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/executive-summary.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Product information and disease description](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/product-information-and-disease-description.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Clinical evidence](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/clinical-evidence.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Economic information and modeling report](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/economics) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/economics.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: References](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/references) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/references.md)
